文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

ICD-10过敏反应算法与Medicare疫苗归因过敏反应发生率估计

ICD-10 anaphylaxis algorithm and the estimate of vaccine-attributable anaphylaxis incidence in Medicare.
PubMed 文献 · Vaccine · 2021-08-09

研究构建含核心与扩展部分的ICD-10过敏反应算法,基于2015—2017年Medicare按服务收费(FFS)理赔数据,并以Brighton协作组病例定义核对病历。2015年10月1日至2019年2月28日共记录66,572,128剂疫苗接种、21,685,119名受益者,接种后2天窗口内识别190例疑似病例,核心算法阳性预测值(PPV)为识别新发过敏反应66%(95%CI [56%, 76%])、疫苗归因过敏反应44%(95%CI [34%, 56%]);任何疫苗接种后疫苗归因过敏反应发生率为0.88/百万剂(95%CI [0.67, 1.16]),提示该人群疫苗归因过敏反应罕见。

要点

  • 核心算法识别新发过敏反应PPV为66%(95%CI [56%, 76%])。
  • 疫苗归因过敏反应PPV为44%(95%CI [34%, 56%])。
  • 任何疫苗接种后疫苗归因过敏反应发生率为0.88/百万剂。

核心结论

  • ICD-10理赔算法可用于真实世界数据中评估过敏反应风险,且显示Medicare FFS受益者中疫苗归因过敏反应罕见。

研究设计与样本

  • 构建含核心与扩展部分的ICD-10过敏反应算法,分析Medicare FFS 2015—2017年理赔数据。
  • 以Brighton协作组过敏反应病例定义结合病历信息判定真实病例。
  • 识别2015年10月1日至2019年2月28日接种后过敏反应病例,并估计接种后2天风险窗口内的PPV与疫苗归因发生率。

主要发现

  • 研究记录66,572,128剂疫苗接种,涉及21,685,119名唯一Medicare FFS受益者。
  • 接种后2天窗口内算法识别190例疑似过敏反应,其中117例(62%)满足核心算法,另73例(38%)满足扩展算法。
  • 核心算法识别新发过敏反应的PPV为66%(95%CI [56%, 76%]),识别疫苗归因过敏反应的PPV为44%(95%CI [34%, 56%])。
  • 任何疫苗接种后疫苗归因过敏反应发生率为0.88/百万剂(95%CI [0.67, 1.16])。

关键数值与推荐

  • 核心算法PPV:新发过敏反应66%(95%CI [56%, 76%]);疫苗归因过敏反应44%(95%CI [34%, 56%])。
  • 疫苗归因过敏反应发生率:任何疫苗接种后0.88/百万剂(95%CI [0.67, 1.16])。
  • 风险窗口:接种后2天。

临床怎么用

  • 可借助ICD-10理赔算法在真实世界数据中监测接种后过敏反应风险。
  • 解读算法结果时需结合其PPV,疫苗归因过敏反应PPV为44%,存在一定假阳性。
  • 监测结果显示Medicare FFS人群疫苗归因过敏反应罕见,可作为风险沟通参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Anaphylaxis is a rare, serious allergic reaction. Its identification in large healthcare databases can help better characterize this risk. OBJECTIVE: To create an ICD-10 anaphylaxis algorithm, estimate its positive predictive values (PPVs) in a post-vaccination risk window, and estimate vaccination-attributable anaphylaxis rates in the Medicare Fee For Service (FFS) population. METHODS: An anaphylaxis algorithm with core and extended portions was constructed analyzing ICD-10 anaphylaxis claims data in Medicare FFS from 2015 to 2017. Cases of post-vaccination anaphylaxis among Medicare FFS beneficiaries were then identified from October 1, 2015 to February 28, 2019 utilizing vaccine relevant anaphylaxis ICD-10 codes. Information from medical records was used to determine true anaphylaxis cases based on the Brighton Collaboration's anaphylaxis case definition. PPVs were estimated for incident anaphylaxis and the subset of vaccine-attributable anaphylaxis within a 2-day post-vaccination risk window. Vaccine-attributable anaphylaxis rates in Medicare FFS were also estimated. RESULTS: The study recorded 66,572,128 vaccinations among 21,685,119 unique Medicare FFS beneficiaries. The algorithm identified a total of 190 suspected anaphylaxis cases within the 2-day post-vaccination window; of these 117 (62%) satisfied the core algorithm, and 73 (38%) additional cases satisfied the extended algorithm. The core algorithm's PPV was 66% (95% CI [56%, 76%]) for identifying incident anaphylaxis and 44% (95% CI [34%, 56%]) for vaccine-attributable anaphylaxis. The vaccine-attributable anaphylaxis incidence rate after any vaccination was 0.88 per million doses (95% CI [0.67, 1.16]). CONCLUSION: The ICD-10 claims algorithm for anaphylaxis allows the assessment of anaphylaxis risk in real-world data. The algorithm revealed vaccine-attributable anaphylaxis is rare among vaccinated Medicare FFS beneficiaries.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Goud R, Thompson D, Welsh K, et al. ICD-10 anaphylaxis algorithm and the estimate of vaccine-attributable anaphylaxis incidence in Medicare. Vaccine. 2021. PMID: 34384636. doi:10.1016/j.vaccine.2021.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。